ロード中...
Combining neratinib with CDK4/6, mTOR and MEK inhibitors in models of HER2-positive cancer
PURPOSE: Neratinib is an irreversible, pan-HER tyrosine kinase inhibitor that is FDA-approved for HER2-overexpressing/amplified (HER2(+)) breast cancer. In this preclinical study, we explored the efficacy of neratinib in combination with inhibitors of downstream signaling in HER2(+) cancers in vitro...
保存先:
| 出版年: | Clin Cancer Res |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8075007/ https://ncbi.nlm.nih.gov/pubmed/33414137 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-3017 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|